Tenderwize
Wróć do wyszukiwania

Non-exclusive Discount Agreement for Epoetin Zeta

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline May 10, 2027 · 207 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Epoetin zeta

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

The authority claims the procedure is not within the scope of EU procurement law due to the Zulassungsmodell. This may...

No minimum or maximum quantities are specified; revenues depend on actual uptake by individual health insurance funds.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Najważniejsze informacje

Zamawiający
GWQ ServicePlus AG
Kraj
Niemcy
CPV
33600000 - Pharmaceutical products
Termin
May 10, 2027

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical products containing the active ingredient Epoetin zeta to German statutory health insurance funds
  • Conclusion of non-exclusive discount agreements with GWQ ServicePlus AG for its member and client health insurance funds
Pokaż pełne podsumowanie

This notice announces a non-exclusive discount agreement for the active ingredient Epoetin zeta, governed by § 130a Abs. 8 SGB V. The GWQ ServicePlus AG, acting for multiple German statutory health insurance funds, invites pharmaceutical companies to conclude discount agreements. The procedure is open to all interested companies with no selection (Zulassungsmodell), and the agreement is intended as a transitional arrangement until exclusive contracts come into force. The contract starts on 1 July 2025 and runs until 30 June 2027. Companies can join at any time during the contract period. The first registration deadline for joining by 1 July 2025 is 10 June 2025.

Ryzyka

The authority claims the procedure is not within the scope of EU procurement law due to the Zulassungsmodell. This may...

No minimum or maximum quantities are specified; revenues depend on actual uptake by individual health insurance funds.

Kluczowe wymagania

Technical

  • Company must be a pharmaceutical enterprise authorized to market Epoetin zeta in Germany

Administrative

  • Submission of signed contract in duplicate, proof of marketing authorization from AMIce database, signed self-declaration (Anlage 3), list of affected PZNs (Anlage 2), and...
  • Contract must be submitted by 10 June 2025 for first registration on 1 July 2025; later submissions may result in later start dates

Zamawiający

Lokalizacja

Düsseldorf, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE258895210

Działalność

Health

Części (1)

LOT-0000

Non-exclusive Discount Agreement for Epoetin Zeta

Non-exclusive rebate agreement for the active ingredient Epoetin zeta with health insurance funds represented by GWQ ServicePlus AG. The agreement is open to all pharmaceutical companies meeting the requirements. Contract start: 1 July 2025; end: 30 June 2027. Companies may join at any time during the contract period.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 10, 2027

Szczegóły zamówienia

Data publikacji
19 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
324849-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30